A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, 4-Period Crossover Study to Evaluate the Effect of GSK2140944 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

Trial Profile

A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, 4-Period Crossover Study to Evaluate the Effect of GSK2140944 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs Gepotidacin (Primary)
  • Indications Respiratory tract infections; Skin and soft tissue infections
  • Focus Adverse reactions
  • Acronyms TQT
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 18 Mar 2017 Results (n=52) assessing effects of SYM-1219 on hERG potassium channel current in vitro and QT interval, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 12 Feb 2017 Results published in the Antimicrobial Agents and Chemotherapy.
    • 14 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top